Point | MustRead The Point for North America Tuesday, 21 July 2026 Morning Call Highlights | Company | Industry | Economics & Strategy | Key Rating and Target Price Changes MorningCallHighlights Ligand Pharmaceuticals (LGND.O) - Resuming Coverage with Buy/H Rating and $387 TP Following Close of XOMA Acquisition Which Opens Up 100+ Shots On Goal We resume coverage of LGND after a period of Rating Suspended with a Buy/H rating and $387 TP post-close of XOMA acquisition. We continue to see upside to current le ...